{"schema_version":"onlylabs.public_signal.v1","title":"Anthropic Writing: Early Progress Drug Development","description":"Anthropic writing signal with public source context, captured evidence pages, related signals, and data-business radar classification.","url":"https://onlylabs.fyi/signals/72d48371-e244-4516-951f-4e8caa6c72fe","json_url":"https://onlylabs.fyi/signals/72d48371-e244-4516-951f-4e8caa6c72fe/signal.json","generated_at":"2026-10-28T12:40:04.389Z","evidence_latest_fetched_at":"2026-10-28T00:03:19.914+00:00","signal_first_seen_at":"2026-10-28T00:00:49.341289+00:00","org":{"slug":"anthropic","name":"Anthropic","category":"frontier-lab","category_label":"Frontier lab","dossier_url":"https://onlylabs.fyi/labs/anthropic","dossier_json_url":"https://onlylabs.fyi/labs/anthropic/dossier.json"},"related_urls":{"signal":"https://onlylabs.fyi/signals/72d48371-e244-4516-951f-4e8caa6c72fe","signal_json":"https://onlylabs.fyi/signals/72d48371-e244-4516-951f-4e8caa6c72fe/signal.json","source":"https://www.anthropic.com/research/early-progress-drug-development","lab_dossier":"https://onlylabs.fyi/labs/anthropic","lab_dossier_json":"https://onlylabs.fyi/labs/anthropic/dossier.json","analysis":"https://onlylabs.fyi/analysis/anthropic","analysis_json":"https://onlylabs.fyi/analysis/anthropic/analysis.json","analysis_evidence_json":"https://onlylabs.fyi/analysis/anthropic/evidence.json","category":"https://onlylabs.fyi/frontier","category_json":"https://onlylabs.fyi/frontier.json","category_feed":"https://onlylabs.fyi/frontier/feed.xml","category_signals_json":"https://onlylabs.fyi/signals.json","topic":"https://onlylabs.fyi/topics/talking","topic_signals_json":"https://onlylabs.fyi/topics/talking/signals.json","topic_feed":"https://onlylabs.fyi/topics/talking/feed.xml","data_business":null},"answer_pack":{"answer":"Anthropic published Early Progress Drug Development. This talking signal gives public context for research themes, product direction, policy, or launch framing. High-signal details: Notable Anthropic research post with good HN traction. · Towards a best-in-class IgE disruptor for food allergy with Claude-enabled antibody design Ezra Erives∗, Emilio Ferrara∗, Sean Michael, Nikhil Mallipeddi, Bowen.... onlylabs links this event to 3 captured evidence pages and 6 related writing signals.","signal_desk":"talking","source_context":{"source_url":"https://www.anthropic.com/research/early-progress-drug-development","source_host":"anthropic.com","occurred_at":"2026-10-27T20:26:09+00:00","first_seen_at":"2026-10-28T00:00:49.341289+00:00","date_source":"sitemap.lastmod","context":null},"context_markers":[{"label":"Lab","value":"Anthropic","source":"signal"},{"label":"Signal desk","value":"talking","source":"signal"},{"label":"Source host","value":"anthropic.com","source":"source"},{"label":"PDF","value":"linked report","source":"source"},{"label":"Notability","value":"Notable Anthropic research post with good HN traction.","source":"signal"},{"label":"HN","value":"Cautious optimism: Claude currently accelerates paperwork and pipelines more than actual drug discovery breakthroughs.","source":"source"},{"label":"Watch term","value":"Infrastructure","source":"evidence"},{"label":"Watch term","value":"Safety and alignment","source":"evidence"},{"label":"Watch term","value":"Agents and tool use","source":"evidence"}],"evidence_coverage":{"target_pages":3,"captured_pages":3,"readable_pages":3,"capture_methods":["firecrawl","plain"],"missing_page_urls":[],"failed_page_urls":[],"blocked_page_urls":[],"page_urls":["https://www.anthropic.com/research/early-progress-drug-development","https://divergencelabs.com/publications/ige-preprint.pdf","https://www-cdn.anthropic.com/52e1f5d50c47ca3818f56704c27cf19e59b62e77.pdf"],"related_signals":6,"has_source_url":true,"latest_page_fetched_at":"2026-10-28T00:03:19.914+00:00"},"data_business":{"matches":false,"lanes":[],"matched_terms":[],"score":null,"reason":null},"agent_handoff":{"signal_json":"https://onlylabs.fyi/signals/72d48371-e244-4516-951f-4e8caa6c72fe/signal.json","dossier_json":"https://onlylabs.fyi/labs/anthropic/dossier.json","analysis_json":"https://onlylabs.fyi/analysis/anthropic/analysis.json","analysis_evidence_json":"https://onlylabs.fyi/analysis/anthropic/evidence.json","topic_signals_json":"https://onlylabs.fyi/topics/talking/signals.json","topic_feed":"https://onlylabs.fyi/topics/talking/feed.xml","category_signals_json":"https://onlylabs.fyi/signals.json","data_radar_json":null,"opportunities_json":null},"analysis_playbook":{"objective":"Turn public writing and discussion into a readable map of research themes, product framing, policy posture, launch narratives, and market attention.","evidence_focus":["post title","source URL","captured page text","HN traction","linked model or paper references","publication date"],"extraction_questions":["Which themes are labs choosing to explain publicly?","Which posts are attracting outside discussion?","Which writing reframes a recent release, model, hiring wave, or policy stance?","Which posts mention data, evals, infrastructure, safety, or deployment workflows?"],"signal_questions":["What public theme, launch framing, or research direction does this writing signal expose?","Which themes are labs choosing to explain publicly?","Which posts are attracting outside discussion?","Do the 6 related writing signals show a repeated pattern?"],"output_fields":["org","theme","public_framing","traction","data_business_lane","evidence_url"],"data_business_relevance":"Public writing supplies the narrative layer over raw signals and helps identify which frontier-lab priorities are becoming externally legible.","required_sources":[{"label":"signal_json","url":"https://onlylabs.fyi/signals/72d48371-e244-4516-951f-4e8caa6c72fe/signal.json","required":true},{"label":"source","url":"https://www.anthropic.com/research/early-progress-drug-development","required":true},{"label":"dossier_json","url":"https://onlylabs.fyi/labs/anthropic/dossier.json","required":true},{"label":"analysis_evidence_json","url":"https://onlylabs.fyi/analysis/anthropic/evidence.json","required":true},{"label":"topic_signals_json","url":"https://onlylabs.fyi/topics/talking/signals.json","required":false},{"label":"data_radar_json","url":null,"required":false}],"expected_output":["one-paragraph source-grounded interpretation","category-specific implication","confidence and missing evidence","recommended next source to inspect"],"prompt_seed":"Using only the linked onlylabs JSON, captured source context, and cited evidence, analyze Anthropic's writing signal \"Early Progress Drug Development\" for frontier lab strategy."},"semantic_triples":[{"subject":"Anthropic","predicate":"published","object":"Early Progress Drug Development","text":"Anthropic published Early Progress Drug Development."},{"subject":"Early Progress Drug Development","predicate":"is classified as","object":"writing signal","text":"Early Progress Drug Development is classified as writing signal."},{"subject":"Early Progress Drug Development","predicate":"belongs to","object":"talking desk","text":"Early Progress Drug Development belongs to talking desk."},{"subject":"Early Progress Drug Development","predicate":"has evidence coverage","object":"3 captured evidence pages","text":"Early Progress Drug Development has evidence coverage 3 captured evidence pages."},{"subject":"Early Progress Drug Development","predicate":"has captured page count","object":"3","text":"Early Progress Drug Development has captured page count 3."},{"subject":"Early Progress Drug Development","predicate":"has readable page count","object":"3","text":"Early Progress Drug Development has readable page count 3."},{"subject":"Early Progress Drug Development","predicate":"has related signal count","object":"6","text":"Early Progress Drug Development has related signal count 6."},{"subject":"Early Progress Drug Development","predicate":"has analysis playbook objective","object":"Turn public writing and discussion into a readable map of research themes, product framing, policy posture, launch narratives, and market attention.","text":"Early Progress Drug Development has analysis playbook objective Turn public writing and discussion into a readable map of research themes, product framing, policy posture, launch narratives, and market attention.."},{"subject":"Early Progress Drug Development","predicate":"has source host","object":"anthropic.com","text":"Early Progress Drug Development has source host anthropic.com."},{"subject":"Early Progress Drug Development","predicate":"has lab","object":"Anthropic","text":"Early Progress Drug Development has lab Anthropic."},{"subject":"Early Progress Drug Development","predicate":"has signal desk","object":"talking","text":"Early Progress Drug Development has signal desk talking."},{"subject":"Early Progress Drug Development","predicate":"has source host","object":"anthropic.com","text":"Early Progress Drug Development has source host anthropic.com."},{"subject":"Early Progress Drug Development","predicate":"has pdf","object":"linked report","text":"Early Progress Drug Development has pdf linked report."},{"subject":"Early Progress Drug Development","predicate":"has notability","object":"Notable Anthropic research post with good HN traction.","text":"Early Progress Drug Development has notability Notable Anthropic research post with good HN traction.."},{"subject":"Early Progress Drug Development","predicate":"has hn","object":"Cautious optimism: Claude currently accelerates paperwork and pipelines more than actual drug discovery breakthroughs.","text":"Early Progress Drug Development has hn Cautious optimism: Claude currently accelerates paperwork and pipelines more than actual drug discovery breakthroughs.."},{"subject":"Early Progress Drug Development","predicate":"has watch term","object":"Infrastructure","text":"Early Progress Drug Development has watch term Infrastructure."},{"subject":"Early Progress Drug Development","predicate":"has watch term","object":"Safety and alignment","text":"Early Progress Drug Development has watch term Safety and alignment."}]},"intelligence":{"signal_desk":"talking","answer":"Anthropic published Early Progress Drug Development. This talking signal gives public context for research themes, product direction, policy, or launch framing. High-signal details: Notable Anthropic research post with good HN traction. · Towards a best-in-class IgE disruptor for food allergy with Claude-enabled antibody design Ezra Erives∗, Emilio Ferrara∗, Sean Michael, Nikhil Mallipeddi, Bowen.... onlylabs links this event to 3 captured evidence pages and 6 related writing signals.","semantic_triples":[{"subject":"Anthropic","predicate":"published","object":"Early Progress Drug Development","text":"Anthropic published Early Progress Drug Development."},{"subject":"Early Progress Drug Development","predicate":"is classified as","object":"writing signal","text":"Early Progress Drug Development is classified as writing signal."},{"subject":"Early Progress Drug Development","predicate":"belongs to","object":"talking desk","text":"Early Progress Drug Development belongs to talking desk."},{"subject":"Early Progress Drug Development","predicate":"has evidence coverage","object":"3 captured evidence pages","text":"Early Progress Drug Development has evidence coverage 3 captured evidence pages."}]},"signal":{"id":"72d48371-e244-4516-951f-4e8caa6c72fe","url":"https://onlylabs.fyi/signals/72d48371-e244-4516-951f-4e8caa6c72fe","json_url":"https://onlylabs.fyi/signals/72d48371-e244-4516-951f-4e8caa6c72fe/signal.json","source_url":"https://www.anthropic.com/research/early-progress-drug-development","title":"Early Progress Drug Development","summary":"Anthropic published a writing signal. onlylabs watches public writing for research themes, product direction, and model-launch context.","context":null,"kind":{"key":"post_published","label":"Writing"},"org":{"slug":"anthropic","name":"Anthropic","category":"frontier-lab"},"occurred_at":"2026-10-27T20:26:09+00:00","first_seen_at":"2026-10-28T00:00:49.341289+00:00","date_source":"sitemap.lastmod","evidence_coverage":{"target_pages":3,"captured_pages":3,"readable_pages":3,"capture_methods":["firecrawl","plain"],"missing_page_urls":[],"failed_page_urls":[],"blocked_page_urls":[],"page_urls":["https://www.anthropic.com/research/early-progress-drug-development","https://divergencelabs.com/publications/ige-preprint.pdf","https://www-cdn.anthropic.com/52e1f5d50c47ca3818f56704c27cf19e59b62e77.pdf"]},"facets":{},"traction":{"github_stars":null,"hn_points":89,"hn_comments":82,"hn_story_id":"50265609","hf_downloads":null,"hf_likes":null},"data_radar":null},"primary_evidence_page":{"is_primary":true,"source_match":true,"url":"https://www.anthropic.com/research/early-progress-drug-development","final_url":"https://www.anthropic.com/research/early-progress-drug-development","title":"Early Progress Drug Development","http_status":200,"content_type":"text/html; charset=utf-8","capture_method":"plain","fetched_at":"2026-10-28T00:02:48.015565+00:00","bytes":329543,"raw_path":"dcad83d827337ce853e769bf19b79a79ad8c761d88eacae14de27814d19f0b1d.html","content_hash":"5796aa318202e3daa679e5c1b89bd0b264a4183c595464723be68fee49863b2e","excerpt_chars":1200,"truncated":true,"excerpt":"Early progress on accelerating drug development with Claude \\ Anthropic Skip to main content Chapter 01 : Case studies Anthropic’s life sciences team is working to accelerate curing disease. Over the past several months, our scientists have engaged in deep research partnerships with six organizations developing new medicines: BigHat Biosciences , Bristol Myers Squibb , Divergence Labs , Enveda , Generate Biomedicines , and The Column Group . We've also begun drug discovery efforts of our own. In doing so, we've learned a lot about how Claude can support drug development, and how we’ll need to improve Claude further to realize AI's potential in medicine. We plan to scale this work up substantially from here . There are many opportunities to speed up drug development, even beyond the most commonly discussed applications of AI, like proposing initial designs for new molecules. Developing a drug involves many varied tasks: doing early research to identify a target for a drug and the right type of drug to engage it, designing a molecule with the right properties, optimizing it to be manufactured reliably at scale, drafting the regulatory filings needed to run clinical..."},"evidence_pages":[{"is_primary":false,"source_match":false,"url":"https://divergencelabs.com/publications/ige-preprint.pdf","final_url":"https://divergencelabs.com/publications/ige-preprint.pdf","title":"Early Progress Drug Development","http_status":200,"content_type":"application/pdf","capture_method":"firecrawl","fetched_at":"2026-10-28T00:03:19.914+00:00","bytes":20632648,"raw_path":"2086ec152456586631a89823eafe3942fe06b8b1110c346495af623f6aeb21e7.pdf","content_hash":"b0fb64b3ddfc9d8798b32a38415ed23b0d615eda8b89c6e81145452eb0b33548","excerpt_chars":1200,"truncated":true,"excerpt":"Towards a best-in-class IgE disruptor for food allergy with Claude-enabled antibody design Ezra Erives∗, Emilio Ferrara∗, Sean Michael, Nikhil Mallipeddi, Bowen Jing‡∗These authors contributed equally‡Correspondence to: [bowen@divergencelabs.com](mailto:bowen@divergencelabs.com) Divergence Labs Abstract Food allergy affects an estimated 220–250 million people worldwide, for whom the constant risk of a severe reaction weighs heavily on quality of life. Allergic reactions are triggered by the cross-linking of allergen-specific IgE bound to its high-affinity receptor, FcεRI, on mast cells and basophils, causing degranulation, inflammation and, in severe cases, anaphylaxis. Omalizumab (Xolair), the sole FDA-approved biologic for food allergy, neutralizes circulating IgE; however, it does not effectively remove IgE from FcεRI, where it can persist for weeks and where even a small residual amount can sustain sensitivity. Here we describe an agentic computational design campaign with Claude toward a disruptive inhibitor antibody that physically removes bound IgE from FcεRI. Guided by our research team, Claude pursued a biparatopic molecule that pairs a _disruptor arm,_ which displaces..."},{"is_primary":false,"source_match":false,"url":"https://www-cdn.anthropic.com/52e1f5d50c47ca3818f56704c27cf19e59b62e77.pdf","final_url":"https://www-cdn.anthropic.com/52e1f5d50c47ca3818f56704c27cf19e59b62e77.pdf","title":"Early Progress Drug Development","http_status":200,"content_type":"application/pdf","capture_method":"firecrawl","fetched_at":"2026-10-28T00:03:19.887+00:00","bytes":13734746,"raw_path":"bb53142f1c3f54e0bea9defc895fe740a01650646a314d2c7fde9145b752bd80.pdf","content_hash":"ad7b55944eccfd0de47677cbe176916e5111f77004244eac7989ed9d0b3cee56","excerpt_chars":1200,"truncated":true,"excerpt":"Preclinical Characterization of a Bispecific Bridging Antibody for the Treatment of LAMA2-Related Congenital Muscular Dystrophy Cody Tranbarger1,\\* and Mithril Medicine† Cody Tranbarger 1,\\* and Mithril Medicine † 1Anthropic, San Francisco, CA, USA. †Members are listed in the Acknowledgments. \\*Correspondence: [ctranbarger@anthropic.com](mailto:ctranbarger@anthropic.com) Abstract LAMA2-related congenital muscular dystrophy (LAMA2-CMD) is a devastating pediatric disease caused by the loss of laminin-α2 for which there is no disease-modifying treatment. Laminin-α2 is the α chain of laminin-211, the heterotrimer that assembles the basement membrane around each muscle fiber and anchors it to the sarcolemma. Muscle lacking laminin-α2 overexpresses a related laminin, laminin-α4, but the protein fails to self-polymerize and binds α-dystroglycan only weakly, and thus fails to compensate for the missing laminin-α2. We hypothesized that a bispecific antibody bridging laminin-α4 to β-dystroglycan (β-DG), the transmembrane subunit of dystroglycan, would restore basement membrane anchorage and sarcolemma stability. We engineered such bispecific bridging antibodies in several formats and..."}],"related_signals":[{"id":"fc30becf-acec-41fd-adf5-b3356a8f1622","url":"https://onlylabs.fyi/signals/fc30becf-acec-41fd-adf5-b3356a8f1622","source_url":"https://www.anthropic.com/research/claude-discovers-novel-enzyme-system","title":"Claude Discovers Novel Enzyme System","context":null,"kind":{"key":"post_published","label":"Writing"},"org":{"slug":"anthropic","name":"Anthropic","category":"frontier-lab"},"occurred_at":"2026-10-28T04:28:01+00:00","first_seen_at":"2026-10-21T00:00:50.790103+00:00","date_source":"sitemap.lastmod"},{"id":"8fe8c5b5-5c4d-4311-831f-cdcc1ae63a83","url":"https://onlylabs.fyi/signals/8fe8c5b5-5c4d-4311-831f-cdcc1ae63a83","source_url":"https://www.anthropic.com/news/expanding-partnership-gsa","title":"Expanding Partnership Gsa","context":null,"kind":{"key":"post_published","label":"Writing"},"org":{"slug":"anthropic","name":"Anthropic","category":"frontier-lab"},"occurred_at":"2026-10-27T22:21:46+00:00","first_seen_at":"2026-10-28T00:00:49.341289+00:00","date_source":"sitemap.lastmod"},{"id":"fcd9bec3-59c4-4369-abaa-fe1cdcdf27a6","url":"https://onlylabs.fyi/signals/fcd9bec3-59c4-4369-abaa-fe1cdcdf27a6","source_url":"https://www.anthropic.com/news/s1-sec","title":"S1 Sec","context":null,"kind":{"key":"post_published","label":"Writing"},"org":{"slug":"anthropic","name":"Anthropic","category":"frontier-lab"},"occurred_at":"2026-10-27T21:40:46+00:00","first_seen_at":"2026-10-26T16:00:49.313123+00:00","date_source":"sitemap.lastmod"},{"id":"d6c22bc2-acf5-4f1b-b292-31a8d67417e7","url":"https://onlylabs.fyi/signals/d6c22bc2-acf5-4f1b-b292-31a8d67417e7","source_url":"https://www.anthropic.com/research/agents-judgment-calls","title":"Agents Judgment Calls","context":null,"kind":{"key":"post_published","label":"Writing"},"org":{"slug":"anthropic","name":"Anthropic","category":"frontier-lab"},"occurred_at":"2026-10-27T19:17:23+00:00","first_seen_at":"2026-10-27T20:00:49.587113+00:00","date_source":"sitemap.lastmod"},{"id":"8985d414-e798-47ae-afa7-6cb06116a195","url":"https://onlylabs.fyi/signals/8985d414-e798-47ae-afa7-6cb06116a195","source_url":"https://www.anthropic.com/research/discovering-vulnerabilities-with-claude","title":"Discovering Vulnerabilities With Claude","context":null,"kind":{"key":"post_published","label":"Writing"},"org":{"slug":"anthropic","name":"Anthropic","category":"frontier-lab"},"occurred_at":"2026-10-27T18:15:30+00:00","first_seen_at":"2026-10-27T20:00:49.587113+00:00","date_source":"sitemap.lastmod"},{"id":"92d79ccc-0504-4499-a191-695c9e946dea","url":"https://onlylabs.fyi/signals/92d79ccc-0504-4499-a191-695c9e946dea","source_url":"https://www.anthropic.com/research/coding-agents-social-sciences","title":"Coding Agents Social Sciences","context":null,"kind":{"key":"post_published","label":"Writing"},"org":{"slug":"anthropic","name":"Anthropic","category":"frontier-lab"},"occurred_at":"2026-05-27T00:00:00.000Z","first_seen_at":"2026-06-09T02:17:26.339488+00:00","date_source":"page.visible_date"}]}